PRP is the best-supported orthobiologic for canine joint disease, with clinical evidence demonstrating pain and lameness improvements across multiple joint conditions, while mesenchymal stem cell (MSC) therapy shows comparable promise but greater protocol heterogeneity, and autologous conditioned serum (ACS) represents an emerging alternative with distinct anti-inflammatory properties.Journal of the…+2
PRP produces clinically meaningful reductions in pain and functional scores in dogs with osteoarthritis (OA). In dogs with bilateral hip OA, two intra-articular PRP injections 14 days apart produced significant improvements in weight distribution, joint flexion/extension, and validated clinical scores from day 8 through day 180, with radiographic stabilization or improvement in the PRP group versus radiographic progression in saline controls.Research in Vet… In dogs with hip OA randomized to PRP or placebo, the PRP group showed significantly improved scores and reduced lameness sustained through week 24.Research in Vet… In dogs with chronic cranial cruciate ligament rupture and OA, a single PRP injection produced significant gait improvements on pressure walkway analysis over 3 months.Research in Vet… In dogs with bilateral degenerative hip joint disease treated with two intra-articular injections 30 days apart, PRP reduced Canine Brief Pain Inventory (CBPI) scores by 43%, Visual Analogue Scale for locomotion (VAS-loc) by 43%, and descriptive numerical scale (DNS) scores by 33% at 60 days.Journal of Vete…
PRP is simple to produce, relatively affordable, and deliverable on-site, making it one of few orthobiologic interventions with both anabolic potential and clinical study support in dogs.Journal of the… It is safe for intra-articular use; both autologous and allogeneic administration have been reported as safe in canine patients, and the FDA has granted pre-market approval for a leuko-reduced allogeneic pooled freeze-dried PRP product for use in dogs.Journal of the…+1
Product composition is the central variable governing PRP efficacy, and no standardized protocol currently exists.Journal of the… Platelet count, leukocyte content, activation agent, anticoagulant choice, separation technique, injection volume, number of injections, and administration interval have all differed substantially across published studies.Journal of the… Centrifugation force and time directly influence platelet, leukocyte, and growth factor concentrations in the final product.Journal of the… Interleukin-1 receptor antagonist (IL-1RA) — a key mediator of cartilage protection in OA — appears to be present at low concentrations in canine PRP regardless of centrifugation protocol, which may limit its anti-inflammatory ceiling.Journal of the…
ACS produces up to 40 times the IL-1RA concentration of preprocessed serum, compared to PRP, and in human patients receiving ACS versus PRP, ACS provided superior pain relief while PRP produced earlier clinical improvement.Journal of the… This comparison has not been documented in dogs, and the optimal orthobiologic composition for canine OA specifically has not been established in either species.Journal of the…
MSC therapy — most commonly using adipose-derived stem cells (ADSCs) — produces significant improvements in pain and function in canine joint disease, with a trend toward greater efficacy than PRP in direct comparisons.Journal of Vete… In dogs with bilateral degenerative hip joint disease, ADSC treatment reduced Helsinki Chronic Pain Index (HCPI) scores by 41%, CBPI by 52%, VAS-pain by 51%, and VAS-palpation by 48% at 60 days.Journal of Vete… The CBPI-based success rate at 60 days was 75% for ADSCs versus 25% for PRP, though this difference did not reach statistical significance.Journal of Vete… Both therapies were safe across the treatment period.Journal of Vete…
MSC therapy faces the same standardization challenges as PRP, with differences in cell source, dosage, and injection frequency preventing consensus on optimal protocols.Veterinary Rese… Intra-articular injection and scaffold-based delivery are the primary administration routes under investigation.Veterinary Rese… Infrapatellar fat pad (IPFP)-derived MSCs show the highest proliferation rate among canine adipose tissue sources, and IPFP-derived MSCs combined with autologous PRP gels have shown promising results in canine bone defect models.BMC Veterinary…
Combination therapy with MSCs and PRP has been investigated, with PRP used both as a co-injectate and as a culture supplement to enhance MSC proliferation.BMC Veterinary…+1 A 5–10% platelet lysate in culture media promotes proliferation, expansion, colony formation, and differentiation of MSCs.BMC Veterinary… Intra-articular hyaluronic acid (HA) also improves joint pain and mobility in dogs with OA, and has been used in combination with MSCs.WSAVA Global Gu…
| Agent | Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| PRP (intra-articular) | 2 injections, 14–30 days apart; single injection also studied | CBPI −43%, VAS-loc −43%, DNS −33% at 60 days; benefits sustained to 180 days and week 24 in separate cohorts Journal of Vete…+1 | No standardized platelet count, volume, or activation protocol Journal of the… |
| ADSCs (intra-articular) | 2 injections, 30 days apart | HCPI −41%, CBPI −52%, VAS-pain −51%, VAS-palp −48% at 60 days; 75% CBPI success rate Journal of Vete… | Trend toward superiority over PRP not statistically significant Journal of Vete… |
| ACS (intra-articular) | Not defined in canine literature | Up to 40× IL-1RA vs. preprocessed serum; superior pain relief vs. PRP in humans Journal of the… | No canine clinical comparison to PRP documented Journal of the… |
| HA (intra-articular) | Not specified | Positive effects on pain and function alone or combined with MSCs in dogs with OA WSAVA Global Gu… | Limited veterinary evidence base WSAVA Global Gu… |
Would you like guidance on how centrifugation protocols should be selected to optimize platelet and growth factor yield in canine PRP preparation?